See every side of every news story
Published loading...Updated

Risdiplam & the cost of survival: Is pharma playing fair?

Summary by Finshots
In today’s Finshots, we discuss the economics of Risdiplam and why a pharma battle around the drug raises concerns about the industry’s ethics.But before we begin, if you love keeping up with the buzz in business and finance, make sure to subscribe and join the Finshots club, loved by over 5 lakh readers.Already a subscriber or reading this on the app? You’re all set. Go ahead and enjoy the story!The StoryLet’s start today’s story with a sensiti…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Finshots broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.